Sanjeev Narula serves as Chief Financial and Business Officer at Phathom Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. In this role, he oversees all financial operations, including strategic planning, investor relations, business development, and corporate transactions, playing a key part in driving the company's growth and commercialization efforts for its flagship product, VOQUEZNA (vonoprazan), approved for erosive GERD and H. pylori infection. With more than 25 years of experience in the pharmaceutical and biotechnology sectors, Narula brings a proven track record of leadership in high-growth environments. Prior to joining Phathom in 2021, he was Chief Financial Officer at Ironwood Pharmaceuticals from 2016 to 2021, where he managed finances during key product launches and partnerships. Earlier, he served as Senior Vice President and Chief Accounting Officer at Cubist Pharmaceuticals, contributing to its $9.5 billion acquisition by Merck in 2015, and held senior finance roles at Takeda Pharmaceuticals and Pfizer, honing his expertise in financial modeling, M&A, and capital markets. Narula's achievements include orchestrating multiple equity financings, debt arrangements, and strategic alliances that have fueled innovation and market expansion. At Phathom, his leadership has been instrumental in securing over $500 million in funding post-IPO, enabling the rapid U.S. launch of VOQUEZNA and positioning the company for sustained profitability in the competitive PPI market.